SCHEMBL6163924

SCHEMBL6163924

CN(C)c1cc(NC(=O)OC(C)(C)C)c(NC(=O)CC(=O)c2cccc(-n3ccnn3)c2)cc1-c1ccccc1F

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.32
CYP3A4 P08684 1/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
KMT2A Q03164 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
KAT6A Q92794 2/20 0.32
HCRTR2 O43614 1/20 0.32
NOTUM Q6P988 2/20 0.32
CYP17A1 P05093 1/20 0.31
DNMT1 P26358 1/20 0.31
APOBEC3A P31941 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
MEN1 O00255 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167089 0.95 KEAP1 (0.32) KEAP1ALDH1A1SMN1; SMN2KMT2AL3MBTL1
SCHEMBL7139910 0.89 CYP3A4 (0.34) KEAP1CYP3A4ALDH1A1SMN1; SMN2KAT6A
SCHEMBL5868872 0.87 CYP3A4 (0.40) KEAP1CYP3A4ALDH1A1SMN1; SMN2KMT2A
SCHEMBL6165283 0.87 NOTUM (0.34) KEAP1CYP3A4ALDH1A1SMN1; SMN2NOTUM
SCHEMBL6164712 0.86 L3MBTL1 (0.38) L3MBTL1NOTUM
SCHEMBL6166386 0.86 NOTUM (0.38) ALDH1A1SMN1; SMN2KMT2AL3MBTL1NOTUM
SCHEMBL5868820 0.83 CYP17A1 (0.37) KEAP1CYP3A4ALDH1A1SMN1; SMN2KMT2A
SCHEMBL5558978 0.83 CYP17A1 (0.43) CYP17A1
SCHEMBL6164626 0.83 PTGES (0.32) KMT2AL3MBTL1NOTUM
SCHEMBL7139681 0.81 TSHR (0.36) KEAP1KMT2AHCRTR2NOTUMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 KEAP1 380/4885CYP3A4 190/4885ALDH1A1 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.